Denali Capital Acquisition Corp. Files Q1 2024 10-Q
Ticker: SMNRW · Form: 10-Q · Filed: May 22, 2024 · CIK: 1913577
| Field | Detail |
|---|---|
| Company | Denali Capital Acquisition Corp. (SMNRW) |
| Form Type | 10-Q |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, SPAC, quarterly-report
TL;DR
Denali Capital Acquisition Corp. filed its Q1 2024 10-Q. Details on financials and operations.
AI Summary
Denali Capital Acquisition Corp. filed its 10-Q for the quarterly period ended March 31, 2024. The company, incorporated in the Cayman Islands, is a blank check company. Its principal executive offices are located at 437 Madison Avenue, New York, NY.
Why It Matters
This filing provides an update on Denali Capital Acquisition Corp.'s financial status and operations for the first quarter of 2024, which is crucial for investors tracking the company's progress.
Risk Assessment
Risk Level: low — This is a standard quarterly filing (10-Q) for a SPAC, providing routine financial updates.
Key Players & Entities
- Denali Capital Acquisition Corp. (company) — Registrant
- March 31, 2024 (date) — Quarterly period end date
- 437 Madison Avenue, 27th Floor New York, New York 10022 (address) — Principal Executive Offices
- Cayman Islands (location) — State of incorporation
- 001-41351 (other) — Commission File Number
FAQ
What is the primary business of Denali Capital Acquisition Corp.?
Denali Capital Acquisition Corp. is a blank check company, as indicated by its SIC code [6770].
When is the fiscal year end for Denali Capital Acquisition Corp.?
The fiscal year end for Denali Capital Acquisition Corp. is December 31st (1231).
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 22, 2024.
What period does this 10-Q report cover?
This 10-Q report covers the quarterly period ended March 31, 2024.
What is the principal executive office address for Denali Capital Acquisition Corp.?
The principal executive offices are located at 437 Madison Avenue, 27th Floor, New York, New York 10022.
Filing Stats: 4,638 words · 19 min read · ~15 pages · Grade level 18 · Accepted 2024-05-21 20:03:04
Key Financial Figures
- $0.0001 — LLC Class A ordinary shares, par value $0.0001 per share DECA The Nasdaq Stock Market
- $11.50 — ordinary share at an exercise price of $11.50 per share DECAW The Nasdaq Stock Market
Filing Documents
- ea0206045-10q_denali.htm (10-Q) — 474KB
- ea020604501ex31-1_denali.htm (EX-31.1) — 10KB
- ea020604501ex31-2_denali.htm (EX-31.2) — 10KB
- ea020604501ex32-1_denali.htm (EX-32.1) — 3KB
- ea020604501ex32-2_denali.htm (EX-32.2) — 3KB
- 0001213900-24-045702.txt ( ) — 3976KB
- deca-20240331.xsd (EX-101.SCH) — 43KB
- deca-20240331_cal.xml (EX-101.CAL) — 15KB
- deca-20240331_def.xml (EX-101.DEF) — 239KB
- deca-20240331_lab.xml (EX-101.LAB) — 336KB
- deca-20240331_pre.xml (EX-101.PRE) — 229KB
- ea0206045-10q_denali_htm.xml (XML) — 376KB
FINANCIAL INFORMATION
Part I. FINANCIAL INFORMATION Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - DENALI CAPITAL ACQUISITION CORP. 1 Item 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 25 Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 30 Item 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES 30
OTHER INFORMATION
Part II. OTHER INFORMATION Item 1. LEGAL PROCEEDINGS. 31 Item 1A.
RISK FACTORS
RISK FACTORS 31 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. 31 Item 3. DEFAULTS UPON SENIOR SECURITIES. 31 Item 4. MINE SAFETY DISCLOSURES. 31 Item 5. OTHER INFORMATION 31 Item 6. EXHIBITS. 32
SIGNATURES
Part III. SIGNATURES 33 i This report, including, without limitation, statements under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations," includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including with respect to our proposed business combination with Longevity (as defined below). In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report on Form 10-Q may include, for example, statements about: our ability to select an appropriate target business or businesses; our ability to complete our initial business combination, including our proposed business combination with Longevity Biomedical, Inc. ("Longevity"); our expectations around the performance of the prospective target business or businesses; our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; our potential ability to obtain additional financing to complete our initial busi